来那度胺联合硼替佐米及地塞米松治疗初治多发性骨髓瘤疗效评价  

Evaluation of the efficacy of lenalidomide combined with bortezomib and dexamethasone in the treatment of primary multiple myeloma

作　　者：冯绪梅 任翠爱[2] 于志刚[2] 崔景英[2] FENG Xumei;REN Cuiai;YU Zhigang;CUI Jingying(Department of Internal Medicine,Weifang Medical University,Weifang 261053,China;Department of Hematology,Weifang People's Hospital)

机构地区：[1]潍坊医学院内科学教研室,山东潍坊261053 [2]潍坊市人民医院血液内科

出　　处：《潍坊医学院学报》2018年第6期404-406,共3页Acta Academiae Medicinae Weifang

摘　　要：目的观察来那度胺联合硼替佐米及地塞米松(VRD)方案治疗初治多发性骨髓瘤的疗效。方法回顾性分析2015年1月～2017年6月潍坊市人民医院收治的初治多发性骨髓瘤48例,其中20例接受VRD方案治疗,28例接受BD方案(硼替佐米+地塞米松)治疗。结果 VRD方案组总体反应率ORR(PR及PR以上)为85%,BD组总体反应率ORR(PR及PR以上)为57%.两种化疗方案主要不良反应有白细胞和血小板减少、胃肠道症状、乏力等,经过对症治疗以及调整剂量后均能改善。结论来那度胺联合硼替佐米、地塞米松能明显提高初治多发性骨髓瘤患者的缓解率。来那度胺作为多发性骨髓瘤的关键药物,与硼替佐米、地塞米松联合化疗在疗效上具有协同作用。Objective To evaluate the efficacy of lenalidomide combined with bortezomib and dexamethasone( VRD) in the treatment of multiple myeloma. Methods Forty-eight cases of newly treated multiple myeloma treated in Weifang People’s Hospital from January 2014 to June 2017 were retrospectively analyzed. Among them,20 cases were treated with VRD regimen and 28 cases were treated with BD regimen( bortezomib and dexamethasone). Results The total response rate ORR( PR and PR) of VRD regimen group was 85%,while the BD group was 57%. The main adverse effects of the two chemotherapy regimens were leukopenia and thrombocytopenia,gastrointestinal symptoms,weak,etc.,which can be improved after symptomatic treatment and adjustment of dosage. Conclusion Lenalidomide combined with bortezomib and dexamethasone can significantly improve the remission rate of newly treated patients with multiple myeloma. Lenalidomide as a key drug for multiple myeloma has synergistic effect with bortezomib and dexamethasone combined chemotherapy.

关 键 词：多发性骨髓瘤 来那度胺 硼替佐米 有效率 

分 类 号：R969.4[医药卫生—药理学]